Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) CFO Emily Luisa Hill sold 11,448 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,480.56. Following the completion of the transaction, the chief financial officer directly owned 225,108 shares of the company’s stock, valued at $2,919,650.76. This trade represents a 4.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Replimune Group Stock Up 11.6%
Replimune Group stock traded up $1.59 during mid-day trading on Wednesday, reaching $15.24. 8,269,132 shares of the company were exchanged, compared to its average volume of 5,046,735. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. The firm has a market cap of $1.28 billion, a P/E ratio of -4.51 and a beta of 0.88. The business has a fifty day moving average of $10.34 and a 200 day moving average of $7.64. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $15.68.
Replimune Group (NASDAQ:REPL – Get Free Report) last announced its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Research analysts anticipate that Replimune Group, Inc. will post -2.45 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Report on Replimune Group
Replimune Group News Summary
Here are the key news stories impacting Replimune Group this week:
- Positive Sentiment: $150 million offering priced: Replimune priced a $150 million underwritten public offering, providing additional cash to support development of its oncology pipeline and RP1. The financing appears to have reassured investors about the company’s liquidity and ability to fund operations. Replimune Announces Pricing of $150 Million Underwritten Offering
- Neutral Sentiment: Insider transactions were primarily tax-related: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos sold shares totaling approximately $1.01 million. The filings state that the sales covered tax-withholding obligations tied to vested equity awards, while each executive retained a substantial position; therefore, the transactions provide limited evidence of a change in business confidence. SEC insider transaction filing
- Negative Sentiment: Several law firms publicized a securities class action: The lawsuits cover investors who purchased Replimune securities between October 20, 2025, and April 10, 2026. The allegations claim the company misled investors about the efficacy and commercial viability of RP1 and failed to disclose unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and the lead-plaintiff deadline is October 5, 2026. The notices increase legal and reputational uncertainty, although the allegations have not been proven. REPL Class Action Reminder Levi and Korsinsky class action notice
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC boosted its holdings in Replimune Group by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock worth $157,000 after acquiring an additional 1,505 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Replimune Group by 4.7% during the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock valued at $159,000 after acquiring an additional 1,712 shares in the last quarter. Ballentine Partners LLC increased its holdings in shares of Replimune Group by 7.8% during the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock valued at $230,000 after acquiring an additional 1,721 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares during the last quarter. Finally, Walleye Capital LLC raised its position in shares of Replimune Group by 3.2% in the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock valued at $548,000 after purchasing an additional 2,192 shares during the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.
Replimune Group Company Profile
Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.
Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.
Featured Articles
- Five stocks we like better than Replimune Group
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
